Skip to main content
    T

    Teva Pharma Industries Ltd ADR (TEVA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $42.58
    -1.92 (-4.31%)

    Market Cap: $51.92B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Teva Pharma Industries Ltd ADR (TEVA) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Teva Pharma Industries Ltd ADR reported EPS of $0.83, above the $0.70 estimate. It beat the EPS estimate in each of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(26/39)
    Avg Surprise
    +7.91%
    Streak
    9 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.68
    Range$0.60 - $0.81
    5 analysts
    Revenue Consensus
    $4.34B
    Range$4.11B - $4.53B
    5 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.61
    Range$0.42 - $0.69
    9 analysts
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.63-2.9%
    7d ago$0.63-3.4%
    Current$0.61
    Revenue Consensus
    $4.07B
    Range$4.00B - $4.13B
    7 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 29.2% below the $0.96 reported for the quarter ended Dec 31, 2025.

    TEVA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    TEVA Earnings Call

    The latest TEVA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, TEVA beat 26, missed 9 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $4.39B, down 2.0% from $4.48B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.83$0.70$0.60 - $0.89+18.57%Beat+10.7%12N/ANov 3, 2026$4.39B
    Jun 30, 2026$0.64$0.05-$0.03 - $0.56N/AN/A-3.0%90 up, 3 downJul 29, 2026$4.14B
    Mar 31, 2026$0.53$0.46$0.41 - $0.52+15.22%Beat+1.9%80 up, 8 downApr 29, 2026$3.98B
    Dec 31, 2025$0.96$0.64$0.58 - $0.75+50.00%Beat+35.2%91 up, 3 downJan 28, 2026$4.71B
    Sep 30, 2025$0.75$0.66$0.64 - $0.71+13.64%Beat+8.7%72 up, 3 downNov 5, 2025$4.48B
    Jun 30, 2025$0.66$0.62$0.58 - $0.64+6.45%Beat+8.2%70 up, 3 downJul 30, 2025$4.18B
    Mar 31, 2025$0.52$0.46$0.41 - $0.50+13.04%Beat+8.3%40 up, 3 downMay 7, 2025$3.89B
    Dec 31, 2024$0.71$0.70$0.67 - $0.75+1.43%Beat-29.0%50 up, 1 downJan 29, 2025$4.23B
    Sep 30, 2024$0.69$0.66$0.63 - $0.68+4.55%Beat+15.0%52 up, 0 downNov 6, 2024$4.33B
    Jun 30, 2024$0.61$0.55$0.51 - $0.58+10.91%Beat+8.9%50 up, 2 downJul 31, 2024$4.16B
    Mar 31, 2024$0.48$0.51$0.47 - $0.54-5.88%Miss+20.0%71 up, 0 downMay 8, 2024$3.82B
    Dec 31, 2023$1.00$0.76$0.71 - $0.85+31.58%Beat+40.8%83 up, 0 downJan 31, 2024$4.46B
    Sep 30, 2023$0.60$0.61$0.56 - $0.68-1.64%Miss+1.7%80 up, 0 downNov 8, 2023$3.85B
    Jun 30, 2023$0.56$0.53$0.49 - $0.57+5.66%Beat-17.6%71 up, 0 downAug 2, 2023$3.88B
    Mar 31, 2023$0.40$0.55$0.54 - $0.57-27.27%Miss-27.3%81 up, 0 downMay 10, 2023$3.66B
    Dec 31, 2022$0.71$0.71$0.64 - $0.780.00%In line-7.8%102 up, 0 downFeb 8, 2023$3.88B
    Sep 30, 2022$0.59$0.62$0.58 - $0.67-4.84%Miss0.0%91 up, 0 downNov 3, 2022$3.60B
    Jun 30, 2022$0.68$0.56N/A+21.43%Beat+15.3%N/A1 up, 1 downJul 26, 2022$3.79B
    Mar 31, 2022$0.55$0.55$0.48 - $0.610.00%In line-12.7%131 up, 0 downMay 3, 2022$3.66B
    Dec 31, 2021$0.77$0.73$0.67 - $0.81+5.48%Beat+13.2%140 up, 0 downFeb 9, 2022$4.10B
    Sep 30, 2021$0.59$0.65$0.62 - $0.68-9.23%Miss+1.7%14N/AOct 27, 2021$3.89B
    Jun 30, 2021$0.59$0.59$0.50 - $0.630.00%In line+7.3%16N/AJul 28, 2021$3.91B
    Mar 31, 2021$0.63$0.60$0.56 - $0.63+5.00%Beat-17.1%17N/AApr 28, 2021$3.98B
    Dec 31, 2020$0.68$0.62$0.54 - $0.69+9.68%Beat+9.7%19N/AFeb 10, 2021$4.45B
    Sep 30, 2020$0.58$0.58$0.55 - $0.620.00%In line0.0%18N/ANov 5, 2020$3.98B
    Jun 30, 2020$0.55$0.53$0.50 - $0.60+3.77%Beat-8.3%18N/AAug 5, 2020$3.87B
    Mar 31, 2020$0.76$0.59$0.51 - $0.64+28.81%Beat+26.7%17N/AMay 7, 2020$4.36B
    Dec 31, 2019$0.62$0.61$0.57 - $0.66+1.64%Beat+17.0%19N/AFeb 12, 2020$4.47B
    Sep 30, 2019$0.58$0.59$0.55 - $0.64-1.69%Miss-14.7%19N/ANov 7, 2019$4.26B
    Jun 30, 2019$0.60$0.58$0.51 - $0.94+3.45%Beat-23.1%20N/AAug 7, 2019$4.34B
    Mar 31, 2019$0.60$0.58$0.48 - $0.62+3.45%Beat-36.2%20N/AMay 2, 2019$4.29B
    Dec 31, 2018$0.53$0.55$0.41 - $0.64-3.64%Miss-43.0%19N/AFeb 13, 2019$4.56B
    Sep 30, 2018$0.68$0.54$0.50 - $0.68+25.93%Beat-32.0%18N/ANov 1, 2018$4.53B
    Jun 30, 2018$0.78$0.64$0.51 - $0.74+21.88%Beat-23.5%21N/AAug 2, 2018$4.70B
    Mar 31, 2018$0.94$0.67$0.52 - $0.75+40.30%Beat-11.3%24N/AMay 3, 2018$5.07B
    Dec 31, 2017$0.93$0.76$0.70 - $0.93+22.37%Beat-32.6%22N/AFeb 8, 2018$5.46B
    Sep 30, 2017$1.00$1.03$0.94 - $1.19-2.91%Miss-23.7%22N/ANov 2, 2017$5.61B
    Jun 30, 2017$1.02$1.06$0.92 - $1.17-3.77%Miss-18.4%21N/AAug 3, 2017$5.69B
    Mar 31, 2017$1.06$1.03N/A+2.91%Beat-11.7%N/AN/AMay 11, 2017$5.63B
    Dec 31, 2016$1.38$1.35N/A+2.22%Beat+7.8%N/AN/AFeb 13, 2017$6.49B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.89, up 16.1% from the year before. It was $5.14 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.89+16.1%
    Dec 31, 2024$2.49-2.7%
    Dec 31, 2023$2.56N/A
    Dec 31, 2022$2.53-1.9%
    Dec 31, 2021$2.58N/A
    Dec 31, 2020$2.57+7.1%
    Dec 31, 2019$2.40-18.1%
    Dec 31, 2018$2.93-26.9%
    Dec 31, 2017$4.01-22.0%
    Dec 31, 2016$5.14N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 11,000 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202611,13415
    2026Q2Jun 30, 20266,02714
    2026Q1Mar 31, 20267,31615
    2025Q4Dec 31, 20257,29713
    2025Q3Sep 30, 20258,89213
    2025Q2Jun 30, 20257,78913
    2025Q1Mar 31, 20256,77911
    2024Q4Dec 31, 20245,62013

    2026Q3 Earnings Call

    Opening remarks

    Christopher Stevo Head of Investor Relations Thank you, Elliot. Good morning and good afternoon, everyone. Thank you for joining us for our third quarter earnings call. As usual, our materials are posted to our website this morning, so please feel free to see them there. Before I turn the call over to our CEO, Richard Francis, I would like to remind everyone that we will be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent Forms 10-Q and 10-K filed with the SEC. Any statements that we make are only as of today, and we undertake no obligation to update those statements subsequently. However, I will now undertake the obligation to give you our CEO, Richard Francis.

    Richard Francis CEO Thank you, Chris. Good morning, good afternoon, everybody. Thank you for joining the call. With me today on this call will be Dr. Eric Hughes, Head of Global R&D and Chief Medical Officer, and Eli Kalif, CFO. Moving on to the next slide. As I always do, I start with the pivot to growth strategy and the four pillars. We launched it in 2023, and I am going to give you an update in Q3 on the progress we have made against this strategy. Starting with deliver on our growth engines. You will see that the innovative portfolio continues to perform well. AUSTEDO, AJOVY, and UZEDY are all delivering strong Q3 performance, and our innovative portfolio is up 33%. We are raising full-year guidance across all of these products. Now, the importance of these products can be seen in our financials, and you'll see that our revenue is stronger, our margins and our free cash flow also become stronger. Now looking to the second pillar, step up innovation. You see that we've had eight major milestone readouts this year, but also we've seen some big progress. The approval of UZEDY was a significant moment for Teva as well as the patients suffering from schizophrenia. We also have good progress in the pipeline, and we have FDA fast-track designation for our anti-IL-15 candidate for celiac disease. Looking ahead, we have four additional potential submissions over the next five years. With regard to an announcement we made earlier in the week, emrusolmin, after an independent data monitoring committee met on a prespecified interim futility analysis, we have discontinued the Phase II study. It's worth pointing out there were no safety concerns.

    Frequently Asked Questions About TEVA

    Did TEVA beat earnings estimates last quarter?

    Yes. Teva Pharma Industries Ltd ADR reported EPS of $0.83 for the quarter ended Sep 30, 2026, above the $0.70 estimate, a 18.57% surprise.

    What EPS do analysts expect from TEVA next quarter?

    The consensus EPS estimate for Teva Pharma Industries Ltd ADR for the quarter ending Dec 31, 2026 is $0.68 from 5 analysts, with estimates from $0.60 to $0.81.

    How often does TEVA beat earnings estimates?

    Teva Pharma Industries Ltd ADR beat the EPS estimate in each of the 8 most recent quarters that had an estimate, with an average surprise of +15.36%.